EW News and Press, Edwards Lifesciences Corporation From 10/22/20

Edwards Lifesciences Corporation (EW) Q3 2020 Earnings Conference Call October 21, 2020 17:00 ET Company Participants Mark Wilterding - President, Investor Relations Mike Mussallem - Chairman and Chief Executive Officer Scott Ullem - Chief Financial Officer Conference Call Participants David ...

Edwards Lifesciences (EW) Q3 results:Net sales: $1,140.9M (+4.3%), Transcatheter Aortic Valve Replacement ((TAVR)): $744.6M (+6.4%); Surgical Structural Heart: $203.3M (-0.4%); Critical Care: $180.9M (+0.4%); Transcatheter Mitral and Tricuspid Therapies: $12.1M (+24.7%).Net income: $325.2M (+...

Edwards Lifesciences (EW): Q3 Non-GAAP EPS of $0.51 beats by $0.07; GAAP EPS of $0.52 beats by $0.12.Revenue of $1.14B (+4.6% Y/Y) beats by $60M.FY20 Adj. EPS guidance increased: $1.85-$1.95 from $1.75-$1.95 earlier.2021 TAVR sales expected to return to double-digit growth.Press Release For...

Edwards Lifesciences (NYSE:EW) is scheduled to announce Q3 earnings results on Wednesday, October 21st, after market close.The consensus EPS Estimate is $0.44 (-68.8% Y/Y) and the consensus Revenue Estimate is $1.08B (-1.8% Y/Y).Over the last 2 years, EW has beaten EPS estimates 75% of the ti...

Wedgewood Partners is a money manager founded in 1988 with the goal of providing investors with a superior approach to managing investment portfolios. For the third quarter 2020, our Composite (net) gained +10.77%. The S&P 500 Index gained+8.93%. The Russell 1000 Growth Index gain...

Recent correction and pullback in Baxter's price has turned the tables on valuation, thus presenting an exciting entry point. Current DCF valuation highlights a +5% value gap to the upside. Baxter has bounced off the long-term support line at least 5 times previously, and is curre...

Edwards Lifesciences To Host Earnings Conference Call On October 21, 2020 PR Newswire IRVINE, Calif., Oct. 7, 2020 IRVINE, Calif. , Oct. 7, 2020 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW), plans to announce its operating results for the quarter ende...

Many investors find it difficult to sell high-quality winners. But when high prices push expected future returns low enough, even the stocks of the best businesses should be sold. My goal is to demonstrate the long-term validity of taking profits in overvalued stocks by understanding ...

Medical device stocks look attractive on a long-term and short-term basis. In the long-term, the demand for medical devices continues to increase due to the aging population. In the short-term, there's pent-up demand from the coronavirus leading to a reduction in medical visits and procedures...

This article is part of a series that provides an ongoing analysis of the changes made to Wedgewood Partners' 13F stock portfolio on a quarterly basis. It is based on David Rolfe's regulatory 13F Form filed on 08/14/2020. The 13F portfolio value increased ~12% from $528M to $590M this quarte...